These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3726933)

  • 1. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects.
    Yost RL; Derendorf H
    Ther Drug Monit; 1986; 8(2):189-94. PubMed ID: 3726933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of gender on the disposition of cefotaxime and desacetylcefotaxime.
    Guay DR; Matzke GR; Heim KL; Halstenson CE; Abraham PA; Keane WF
    Ther Drug Monit; 1987 Sep; 9(3):259-62. PubMed ID: 3672567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.
    Heim KL; Halstenson CE; Comty CM; Affrime MB; Matzke GR
    Antimicrob Agents Chemother; 1986 Jul; 30(1):15-9. PubMed ID: 3752976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.
    Ings RM; Fillastre JP; Godin M; Leroy A; Humbert G
    Rev Infect Dis; 1982; 4 Suppl():S379-91. PubMed ID: 6294787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefotaxime and metabolite disposition in two pediatric continuous ambulatory peritoneal dialysis patients.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JA
    Ann Pharmacother; 1992 Mar; 26(3):341-3. PubMed ID: 1554953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
    Albin HC; Demotes-Mainard FM; Bouchet JL; Vincon GA; Martin-Dupont C
    Clin Pharmacol Ther; 1985 Sep; 38(3):285-9. PubMed ID: 4028623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of cefotaxime into respiratory secretions.
    Fick RB; Alexander MR; Prince RA; Kasik JE
    Antimicrob Agents Chemother; 1987 May; 31(5):815-7. PubMed ID: 3606080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver.
    Höffken G; Lode H; Koeppe P; Ruhnke M; Borner K
    Chemotherapy; 1984; 30(1):7-17. PubMed ID: 6319092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans.
    Sjölin J; Eriksson N; Arneborn P; Cars O
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2606-10. PubMed ID: 1810195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates.
    Crooks J; White LO; Burville LJ; Speidel BD; Reeves DS
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():97-101. PubMed ID: 6094467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients.
    Urien S; Laurent N; Barre J; Druguet M; Bouvier D'yvoire M; Maire P
    Eur J Clin Pharmacol; 2004 Mar; 60(1):11-6. PubMed ID: 14767629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The action of beta-lactamases on desacetyl-cefotaxime and cefotaxime.
    Labia R; Morand A; Kazmierczak A
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():45-51. PubMed ID: 6094462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefotaxime disposition pharmacokinetics during peritoneal dialysis.
    Overgaard S; Løkkegaard N; Scrøder S; Fugleberg S; Nielsen-Kudsk F
    Pharmacol Toxicol; 1987 May; 60(5):321-4. PubMed ID: 3615340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of cefotaxime in rat, dog and man.
    Macdonald CM; Fromson JM; McDonald A; Dell D; Chamberlain J; Coombes JD
    Arzneimittelforschung; 1984; 34(12):1719-23. PubMed ID: 6099125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of fever on cefotaxime pharmacokinetics].
    Demotes-Mainard F; Albin H; Ragnaud JM; Gin H; Vincon G; Aubertin J
    Pathol Biol (Paris); 1988 Feb; 36(2):155-8. PubMed ID: 3279384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of cefotaxime and its metabolite, desacetylcefotaxime, in rat: application of a pharmacokinetic-protein binding model.
    Hakim L; Bourne DW; Triggs EJ
    Xenobiotica; 1989 Jul; 19(7):743-54. PubMed ID: 2773510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.
    Regamey C
    Chemotherapy; 1985; 31(2):85-94. PubMed ID: 3987394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function.
    Doluisio JT
    Rev Infect Dis; 1982; 4 Suppl():S333-45. PubMed ID: 6294782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.